{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:40:03Z","timestamp":1745469603462,"version":"3.40.4"},"reference-count":10,"publisher":"S. Karger AG","issue":"Suppl. 2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiol Haemos Thromb"],"published-print":{"date-parts":[[2000]]},"abstract":"<jats:p>Antithrombotic treatment of acute coronary syndromes (ACS) comprises aspirin and (low-molecular-weight) heparin. Adjunctive treatment with intravenous glycoprotein IIb\/IIIa receptor antagonists may be used in high-risk individuals, especially when they undergo percutaneous coronary interventions. Results from large-scale trials studying the efficacy and safety of oral glycoprotein IIb\/IIIa blockers in patients with ACS have been disappointing. Thrombolytic therapy is not indicated in ACS.<\/jats:p>","DOI":"10.1159\/000054177","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T17:26:45Z","timestamp":1050427605000},"page":"122-127","source":"Crossref","is-referenced-by-count":0,"title":["Low-Molecular-Weight Heparin and Other Antithrombotic Agents in the Setting of a Primarily Medical Treatment of Unstable Coronary Artery Disease"],"prefix":"10.1159","volume":"30","author":[{"given":"Freek W.A.","family":"Verheugt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.276.10.811"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91270-2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1879"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509213331203"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609123351103"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382103"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382102"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11179-6"}],"container-title":["Pathophysiology of Haemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/54177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/54177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:24:53Z","timestamp":1745468693000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000054177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":10,"journal-issue":{"issue":"Suppl. 2","published-online":{"date-parts":[[2001,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000054177","archive":["Portico"],"relation":{},"ISSN":["1424-8832","1424-8840"],"issn-type":[{"type":"print","value":"1424-8832"},{"type":"electronic","value":"1424-8840"}],"subject":[],"published":{"date-parts":[[2000]]}}}